查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954633

全球女性性功能障礙 (FSD) 治療市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的分析以及未來預測 (2026-2034)

Female Sexual Dysfunction Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 131 Pages | 商品交期: 請詢問到貨日

價格

女性性功能障礙 (FSD) 治療市場成長驅動因素

2025 年全球女性性功能障礙 (FSD) 治療市場規模為 5.3719 億美元，預計將從 2026 年的 5.9574 億美元增長至 2034 年的 16.5508 億美元，預測期內複合年增長率高達 13.62%。北美地區在 2025 年佔市場主導地位，市佔率高達 88.90%，這得益於較高的認知度、較高的處方率和強勁的研發投入。預計到 2032 年，美國市場規模將達到 7.823 億美元，反映出持續的創新和療法的普及。

女性性功能障礙是指與性慾、性喚起、性反應或疼痛相關的持續性或復發性問題，這些問題會造成痛苦。由於雌激素水平下降，性交疼痛、性慾低下（HSDD）和生殖器-骨盆腔插入疼痛障礙（GPPPD）等症狀在停經後女性中特別常見。此外，糖尿病、癌症和心血管疾病等慢性疾病會增加性功能障礙的風險，並推動對治療的需求。

市場趨勢

市場的一個關鍵趨勢是越來越關注荷爾蒙療法，特別是基於雌激素的療法。局部雌激素療法（LETs），如陰道乳膏、栓劑、膠囊和陰道環，被廣泛用於治療更年期症狀，例如性交疼痛和陰道乾澀。 預計到 2026 年，由於其療效顯著、價格合理且易於給藥，雌激素療法市場佔有率將達到 59.36%。

製藥公司正在擴大其雌激素產品組合，並在新的地區獲得監管部門的批准。 Imvexxy 和 Osphena 等產品的銷售成長凸顯了陰道雌激素療法的日益普及。此外，包括局部使用西地那非乳膏和其他非荷爾蒙療法在內的創新療法的臨床試驗正在進行中，從而拓展了治療選擇。

新冠疫情的影響

由於封鎖、就醫限制和藥品供應減少，新冠疫情在 2020 年暫時阻礙了市場成長。處方量下降，Intrarosa 等關鍵產品的銷售量在疫情期間大幅下滑。 然而，疫情後的復甦、遠距醫療的擴展以及線上藥局的普及，都促使治療需求回升。數位健康領域的合作以及產品商業化的拓展等策略性舉措，也為市場的穩定做出了貢獻。

市場成長因素

研發投入增加

荷爾蒙療法的潛在副作用推動了對更安全的非荷爾蒙療法的需求。因此，製藥公司正大力投資研發，以推出安全性更高的創新藥物。產能的擴大和許可協議的簽署，進一步提高了全球市場的產品供應。

疾病盛行率上升

性交疼痛和性功能障礙（HSDD）的盛行率在全球範圍內不斷上升，尤其是在停經後女性。研究表明，患有慢性疾病的女性性功能障礙的發生率更高。 女性性健康意識的提高和就醫次數的增加促進了診斷和治療率的上升，預計到2034年，市場規模將增長至16.5508億美元。

限制因子

儘管市場成長潛力巨大，但認知度低仍是一個重大障礙。許多女性不了解性功能障礙及其治療方案。社會偏見和不願就醫阻礙了相關療法的進一步普及。此外，發展中地區對荷爾蒙療法和非荷爾蒙療法的認知度較低也限制了市場滲透率。 市場區隔分析 依藥物分類 市場依藥物可細分為氟班色林、布美拉諾肽、奧培米芬、雌激素療法和其他療法。預計到2026年，雌激素療法將佔主導地位，市佔率高達59.36%，這主要歸功於其在治療更年期症狀方面的高處方率。同時，由於臨床研發活動的增加，預計非荷爾蒙療法在預測期內將實現強勁成長。 依疾病分類 依疾病分類，市場包括性慾亢進症 (HSDD)、性交疼痛及其他疾病。性交疼痛細分市場在2026年佔最大佔有率，達到90.81%，這主要得益於其全球高發病率和日益增長的臨床關注。由於人們對心理健康的認識不斷提高，性慾亢進症細分市場預計將保持穩定成長。 依給藥途徑分類 市場依給藥途徑分為口服、注射及局部用藥。注射給藥途徑在2026年佔主導地位，市佔率達70.70%，主要得益於其局部給藥和減少全身副作用等優勢。然而，由於產品不斷創新，局部用藥預計未來將獲得更多關注。

依通路劃分

預計到2026年，醫院藥局將佔65.55%的市場。這主要得益於就診量的增加以及處方藥的便捷取得。零售藥局和網路藥局也因其便利性和與遠距醫療的整合而迅速擴張。

區域洞察

預計到2025年，北美將以4.7739億美元的市場規模引領市場，這得益於先進的醫療基礎設施、較高的公眾認知度以及產品審批。歐洲將佔第二大市場佔有率，這主要得益於積極的臨床研究和監管措施。亞太地區預計將實現最高的複合年增長率，這主要得益於公眾認知度的提高、老年女性人口的增長以及醫療服務可及性的改善。拉丁美洲和中東及非洲地區預計將實現溫和成長，這主要得益於監管措施和疾病認知度的提高。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要疾病盛行率：依主要國家/地區劃分（2025 年）
  • 在開發產品分析
  • 主要產業趨勢：併購、業務合作
  • 新冠疫情對全球市場的影響

第五章 全球女性性功能障礙治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物分類
    • 氟班色林
    • 布雷梅拉諾肽
    • 奧斯培米芬
    • 雌激素療法
    • 其他
  • 市場分析、洞察與預測：依疾病分類
    • 性慾亢進症 (HSDD)
    • 性交疼痛
    • 其他
  • 市場分析與洞察 • 預測：依給藥途徑分類
    • 口服
    • 腸外給藥
    • 外用
  • 市場分析、洞察與預測：依分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析，洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美女性性功能障礙治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第七章 亞太地區女性性功能障礙治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞亞洲
    • 其他亞太地區

第八章 拉丁美洲女性性功能障礙治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第九章 中東與非洲女性性功能障礙治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 其他中東和非洲國家

第十章 競爭分析

  • 全球市佔率分析（2025）
  • 公司公司簡介
    • Sprout Pharmaceuticals, Inc.
    • Mayne Pharma Group Limited
    • Duchesnay Pharmaceutical Group Inc.
    • PALATIN
    • Freya Pharma Solutions B.V.
    • Acerus Pharmaceuticals Corporation
    • Millicent Pharma Ltd. (Endoceutics, Inc.)
    • Pfizer Inc.
Product Code: FBI100850

Growth Factors of female sexual dysfunction (FSD) treatment Market

The global female sexual dysfunction (FSD) treatment market was valued at USD 537.19 million in 2025 and is projected to grow from USD 595.74 million in 2026 to USD 1,655.08 million by 2034, registering a strong CAGR of 13.62% during the forecast period. North America dominated the market with an 88.90% share in 2025, driven by high awareness, strong prescription rates, and robust R&D investments. The U.S. market is projected to reach USD 782.3 million by 2032, reflecting continued innovation and treatment adoption.

Female sexual dysfunction refers to persistent or recurrent issues related to sexual desire, arousal, response, or pain that cause distress. Conditions such as dyspareunia, hypoactive sexual desire disorder (HSDD), and genito-pelvic penetration pain disorder (GPPPD) are particularly prevalent among post-menopausal women due to declining estrogen levels. Additionally, chronic illnesses such as diabetes, cancer, and cardiovascular diseases increase the likelihood of sexual dysfunction, thereby driving treatment demand.

Market Trends

A key trend in the market is the growing focus on hormonal therapies, particularly estrogen-based treatments. Local estrogen therapies (LET), including creams, vaginal tablets, capsules, and rings, are widely prescribed for menopausal symptoms such as dyspareunia and vaginal dryness. In 2026, the estrogen therapy segment accounted for 59.36% of the market share, owing to its effectiveness, affordability, and ease of administration.

Pharmaceutical companies are expanding their estrogen product portfolios and securing regulatory approvals in new regions. Increased sales of products such as Imvexxy and Osphena highlight the rising adoption of vaginal estrogen therapies. Additionally, ongoing clinical trials for innovative therapies, including topical sildenafil cream and other non-hormonal treatments, are expanding the treatment landscape.

COVID-19 Impact

The COVID-19 pandemic temporarily hindered market growth in 2020 due to lockdowns, restricted hospital visits, and reduced drug availability. Prescription volumes declined, and sales of key products such as Intrarosa dropped significantly during the pandemic. However, post-pandemic recovery, telehealth expansion, and improved access to online pharmacies restored treatment demand. Strategic initiatives such as digital health partnerships and expanded product commercialization helped stabilize the market.

Market Growth Drivers

Rising R&D Investments

The potential side effects associated with hormonal therapies have increased demand for safer, non-hormonal alternatives. As a result, pharmaceutical companies are investing heavily in research and development to introduce innovative drugs with improved safety profiles. Manufacturing expansions and licensing agreements are further strengthening product availability across global markets.

Increasing Disease Prevalence

The prevalence of dyspareunia and HSDD among women, especially post-menopausal populations, is rising globally. Studies indicate high rates of sexual dysfunction among women with chronic conditions. Growing awareness of women's sexual health and increased medical consultations are contributing to higher diagnosis and treatment rates, supporting the market's projected expansion to USD 1,655.08 million by 2034.

Restraining Factors

Despite growth prospects, low awareness remains a significant barrier. A large proportion of women are unaware of sexual dysfunction disorders or available treatments. Social stigma and reluctance to seek medical consultation further limit adoption. Additionally, limited awareness of hormonal and non-hormonal therapies in developing regions restricts market penetration.

Market Segmentation Analysis

By Drug

The market is segmented into flibanserin, bremelanotide, ospemifene, estrogen therapy, and others. The estrogen therapy segment dominated with 59.36% share in 2026, driven by high prescription rates for menopausal symptoms. Meanwhile, non-hormonal therapies are expected to witness strong growth during the forecast period due to increasing clinical development activities.

By Disease

Based on disease, the market includes HSDD, dyspareunia, and others. The dyspareunia segment held the largest share of 90.81% in 2026, attributed to its high global prevalence and increased clinical focus. The HSDD segment is projected to grow steadily due to rising awareness and psychological health considerations.

By Route of Administration

The market is categorized into oral, parenteral, and topical routes. The parenteral segment dominated with 70.70% share in 2026, owing to advantages such as localized drug delivery and reduced systemic side effects. However, topical therapies are expected to gain traction with ongoing product innovations.

By Distribution Channel

Hospital pharmacies accounted for 65.55% share in 2026, driven by increased hospital visits and strong availability of prescription therapies. Retail and online pharmacies are also expanding rapidly due to convenience and telehealth integration.

Regional Insights

North America led the market with USD 477.39 million in 2025, supported by advanced healthcare infrastructure, high awareness, and product approvals. Europe holds the second-largest share due to active clinical research and regulatory initiatives. Asia Pacific is projected to witness the highest CAGR, driven by rising awareness, growing elderly female populations, and improved healthcare access. Latin America and the Middle East & Africa are expected to grow moderately with increasing regulatory initiatives and disease awareness.

Competitive Landscape

The market is relatively consolidated, with major players such as Pfizer Inc., Duchesnay Pharmaceutical Group Inc., Mayne Pharma Group Limited, PALATIN, and Sprout Pharmaceuticals leading the industry. Strong product portfolios, strategic partnerships, and licensing agreements are key competitive strategies.

Conclusion

The global female sexual dysfunction treatment market is poised for substantial growth, increasing from USD 537.19 million in 2025 to USD 595.74 million in 2026, and projected to reach USD 1,655.08 million by 2034 at a CAGR of 13.62%. Rising disease prevalence, strong R&D investments, growing awareness of women's sexual health, and expanded telehealth services are key drivers. Despite challenges such as low awareness and social stigma, continuous innovation and regulatory advancements are expected to support sustained long-term market expansion worldwide.

Growth Rate CAGR of 13.62% from 2026-2034

Segmentation By Drug

  • Flibanserin
  • Bremelanotide
  • Ospemifene
  • Estrogen Therapy
  • Others

By Disease

  • Hypoactive Sexual Desire Disorder (HSDD)
  • Dyspareunia
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug, Disease, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Drug, Disease, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases - by Key Countries/Sub-regions, 2025
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Impact of COVID-19 on the Global Market

5. Global Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Flibanserin
    • 5.1.2. Bremelanotide
    • 5.1.3. Ospemifene
    • 5.1.4. Estrogen Therapy
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease
    • 5.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 5.2.2. Dyspareunia
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East and Africa

6. North America Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Flibanserin
    • 6.1.2. Bremelanotide
    • 6.1.3. Ospemifene
    • 6.1.4. Estrogen Therapy
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease
    • 6.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 6.2.2. Dyspareunia
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.5.1. U.K.
    • 6.5.2. Germany
    • 6.5.3. France
    • 6.5.4. Spain
    • 6.5.5. Italy
    • 6.5.6. Rest of Europe

7. Asia Pacific Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Flibanserin
    • 7.1.2. Bremelanotide
    • 7.1.3. Ospemifene
    • 7.1.4. Estrogen Therapy
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease
    • 7.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 7.2.2. Dyspareunia
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. Japan
    • 7.5.2. China
    • 7.5.3. India
    • 7.5.4. Australia
    • 7.5.5. Southeast Asia
    • 7.5.6. Rest of Asia Pacific

8. Latin America Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Flibanserin
    • 8.1.2. Bremelanotide
    • 8.1.3. Ospemifene
    • 8.1.4. Estrogen Therapy
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease
    • 8.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 8.2.2. Dyspareunia
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Rest of Latin America

9. Middle East & Africa Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Flibanserin
    • 9.1.2. Bremelanotide
    • 9.1.3. Ospemifene
    • 9.1.4. Estrogen Therapy
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease
    • 9.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 9.2.2. Dyspareunia
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. GCC
    • 9.5.2. South Africa
    • 9.5.3. Rest of Middle East & Africa

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Sprout Pharmaceuticals, Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. financials (Based on Availability)
    • 10.2.2. Mayne Pharma Group Limited
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. financials (Based on Availability)
    • 10.2.3. Duchesnay Pharmaceutical Group Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. financials (Based on Availability)
    • 10.2.4. PALATIN
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. financials (Based on Availability)
    • 10.2.5. Freya Pharma Solutions B.V.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. financials (Based on Availability)
    • 10.2.6. Acerus Pharmaceuticals Corporation
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. financials (Based on Availability)
    • 10.2.7. Millicent Pharma Ltd. (Endoceutics, Inc.)
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. financials (Based on Availability)
    • 10.2.8. Pfizer Inc.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. financials (Based on Availability)

List of Tables

  • Table 01: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 02: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 03: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 04: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 05: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Region, 2021-2034
  • Table 06: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 07: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 08: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 09: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Country/Sub-region, 2021-2034
  • Table 11: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 12: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 13: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 14: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 15: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Country/Sub-region, 2021-2034
  • Table 16: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 17: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 18: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 19: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Country/Sub-region, 2021-2034
  • Table 21: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 22: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 23: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 24: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Female Sexual Dysfunction Treatment Market Revenue Breakdown (USD million, %) by Region, 2026 & 2034
  • Figure 02: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Drug, 2026 & 2034
  • Figure 03: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Disease, 2026 & 2034
  • Figure 04: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Route of Administration, 2026 & 2034
  • Figure 05: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 06: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Region, 2026 & 2034
  • Figure 07: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 08: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 09: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 10: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 11: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 12: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 14: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Country/Sub-region, 2026 & 2034
  • Figure 16: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Country/Sub-region, 2025
  • Figure 17: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 18: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 19: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 20: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 21: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 22: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 24: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Country/Sub-region, 2026 & 2034
  • Figure 26: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Country/Sub-region, 2025
  • Figure 27: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 28: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 29: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 30: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 31: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 32: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 34: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Country/Sub-region, 2026 & 2034
  • Figure 36: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Country/Sub-region, 2025
  • Figure 37: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 38: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 39: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 40: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 41: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 42: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 44: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Global Female Sexual Dysfunction Treatment Market Share (%), By Company, 2025